Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The PRiME Study: PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma

NCT03299309 is registered in ClinicalTrials.gov with Daniel Landi as lead sponsor.

NCT NCT03299309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03299309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The PRiME Study: PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma
Lead sponsor
Daniel Landi
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 29, 2018
Completion date
May 31, 2027
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant glioma, recurrent brain tumor, childhood, recurrent medulloblastoma